NO20034433L - Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil - Google Patents
Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracilInfo
- Publication number
- NO20034433L NO20034433L NO20034433A NO20034433A NO20034433L NO 20034433 L NO20034433 L NO 20034433L NO 20034433 A NO20034433 A NO 20034433A NO 20034433 A NO20034433 A NO 20034433A NO 20034433 L NO20034433 L NO 20034433L
- Authority
- NO
- Norway
- Prior art keywords
- rapamycin
- fluorouracil
- atineoplastic
- gemcitabine
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28238501P | 2001-04-06 | 2001-04-06 | |
US28238801P | 2001-04-06 | 2001-04-06 | |
PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034433D0 NO20034433D0 (no) | 2003-10-03 |
NO20034433L true NO20034433L (no) | 2003-11-25 |
Family
ID=26961412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034433A NO20034433L (no) | 2001-04-06 | 2003-10-03 | Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1385551B1 (de) |
JP (1) | JP2004525950A (de) |
KR (1) | KR100862178B1 (de) |
CN (1) | CN1309421C (de) |
AT (1) | ATE406892T1 (de) |
AU (1) | AU2007242958A1 (de) |
BR (1) | BR0208627A (de) |
CA (1) | CA2442849A1 (de) |
DE (1) | DE60228699D1 (de) |
EA (1) | EA010184B1 (de) |
ES (1) | ES2312568T3 (de) |
HK (1) | HK1060062A1 (de) |
HU (1) | HUP0304093A3 (de) |
IL (1) | IL157898A0 (de) |
MX (1) | MXPA03009092A (de) |
NO (1) | NO20034433L (de) |
NZ (1) | NZ540047A (de) |
PL (1) | PL363991A1 (de) |
PT (1) | PT1385551E (de) |
SG (1) | SG152906A1 (de) |
SI (1) | SI1385551T1 (de) |
WO (1) | WO2002080975A1 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
SI2762140T1 (sl) | 2001-02-19 | 2017-07-31 | Novartis Ag | Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina |
GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
EA011488B1 (ru) | 2002-02-01 | 2009-04-28 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их получение |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
EP1683785B1 (de) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Harnstoffderivate und verfahren zu deren herstellung |
EP1732583A4 (de) * | 2004-02-26 | 2009-08-12 | Penn State Res Found | Kombinationstherapien zur behandlung von neoplasie unter verwendung des opioid-wachstumsfaktor-rezeptors |
WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
EP1942937A1 (de) * | 2005-11-04 | 2008-07-16 | Wyeth | Antitumor-kombinationen mit mtor-hemmer, herceptin und/oder hki-272 |
CA2629714A1 (en) * | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of an mtor inhibitor to treat patients with cancer |
GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
NO20220050A1 (no) * | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
JP2009523149A (ja) * | 2006-01-12 | 2009-06-18 | ノバルティス アクチエンゲゼルシャフト | mTOR阻害剤および抗葉酸化合物の組み合わせ |
EP1880723A1 (de) * | 2006-07-14 | 2008-01-23 | Novartis AG | Kombination aus mTOR Inhibitor und Antifolat Verbindung |
WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
JP2009532503A (ja) * | 2006-04-05 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | 癌を処置するための治療剤の組合せ |
CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
WO2008016633A2 (en) * | 2006-08-02 | 2008-02-07 | Ariad Gene Therapeutics, Inc. | Combination therapy |
CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
EP2087113A2 (de) * | 2006-10-11 | 2009-08-12 | Fusion Antibodies Limited | Kombinationstherapie |
JP2010509400A (ja) | 2006-11-14 | 2010-03-25 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 経口処方組成物 |
JPWO2008088088A1 (ja) | 2007-01-19 | 2010-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 膵癌治療用組成物 |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
PT2481409T (pt) * | 2007-03-07 | 2018-10-18 | Abraxis Bioscience Llc | Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno |
AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
NZ616613A (en) | 2008-06-17 | 2015-05-29 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
AU2009279771B2 (en) | 2008-08-04 | 2015-05-14 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
HUE061640T2 (hu) | 2009-04-06 | 2023-07-28 | Wyeth Llc | Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával |
EP2586443B1 (de) | 2010-06-25 | 2016-03-16 | Eisai R&D Management Co., Ltd. | Antitumorwirkstoff mit verbindungen mit kinasehemmungswirkung in kombination |
AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
AU2014266223B2 (en) | 2013-05-14 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
PL3524595T3 (pl) | 2014-08-28 | 2022-10-31 | Eisai R&D Management Co., Ltd. | Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania |
HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
SG10202009423QA (en) | 2016-03-28 | 2020-11-27 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
CA2278056C (en) * | 1997-01-24 | 2006-12-12 | Norsk Hydro Asa | Gemcitabine derivatives |
TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
- 2002-04-05 EP EP02726710A patent/EP1385551B1/de not_active Expired - Lifetime
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active IP Right Cessation
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en active Application Filing
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2004
- 2004-04-30 HK HK04103071A patent/HK1060062A1/xx not_active IP Right Cessation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EA010184B1 (ru) | 2008-06-30 |
DE60228699D1 (de) | 2008-10-16 |
EA200301091A1 (ru) | 2004-02-26 |
HUP0304093A2 (hu) | 2004-04-28 |
ATE406892T1 (de) | 2008-09-15 |
NZ540047A (en) | 2007-01-26 |
AU2007242958A1 (en) | 2008-01-10 |
CN1309421C (zh) | 2007-04-11 |
EP1385551B1 (de) | 2008-09-03 |
HUP0304093A3 (en) | 2008-08-28 |
IL157898A0 (en) | 2004-03-28 |
KR20040007491A (ko) | 2004-01-24 |
WO2002080975A1 (en) | 2002-10-17 |
HK1060062A1 (en) | 2004-07-30 |
MXPA03009092A (es) | 2004-02-12 |
CN1545419A (zh) | 2004-11-10 |
CA2442849A1 (en) | 2002-10-17 |
JP2004525950A (ja) | 2004-08-26 |
SG152906A1 (en) | 2009-06-29 |
EP1385551A1 (de) | 2004-02-04 |
BR0208627A (pt) | 2004-03-09 |
PL363991A1 (en) | 2004-11-29 |
ES2312568T3 (es) | 2009-03-01 |
PT1385551E (pt) | 2008-11-03 |
NO20034433D0 (no) | 2003-10-03 |
SI1385551T1 (sl) | 2008-12-31 |
KR100862178B1 (ko) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20034433D0 (no) | Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil | |
ECSP045245A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados | |
ECSP056001A (es) | Combinaciones antineoplásicas | |
NO20034094L (no) | Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat | |
NO20035366L (no) | Benzoylsulfonamider og sulfonylbenzamidiner for anvendelse som antitumormidler | |
BR0211769A (pt) | Combinações antineoplásicas | |
NO20032181D0 (no) | Anvendelse av CCI-779 som et antineoplastisk middel | |
AR028512A1 (es) | Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas | |
NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
NO20041998D0 (no) | Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem | |
NO20052534D0 (no) | Oksazolidinon- og/eller isokazolinderivater som antibakterielle stoffer | |
NO20061402L (no) | Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler | |
NO20025150L (no) | 2-acylindolderivater og deres anvendelse som antitumormidler | |
NO20043313L (no) | Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner | |
NO20071871L (no) | Fosfoindoler som HIV-inhibitorer. | |
HUP0300848A2 (hu) | Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére | |
BR0210101A (pt) | Combinações antineoplásticas | |
ECSP034813A (es) | Arilsulfonamidas como agentes antivirales | |
ECSP034790A (es) | Combinaciones antineoplásticas tales como rapamicin junto con gemcitabina o fluorouracil | |
ITRM20030363A0 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse. | |
ITVR20010031A0 (it) | Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative. | |
ATE400285T1 (de) | Mischungen von isoflavonen und flavonen | |
IT1317920B1 (it) | S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |